NCT05039801 2026-04-15IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsM.D. Anderson Cancer CenterPhase 1 Recruiting54 enrolled
NCT05005403 2026-04-13Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanAbbViePhase 1 Recruiting694 enrolled
NCT05063552 2026-04-13Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersNational Cancer Institute (NCI)Phase 2/3 Active not recruiting430 enrolled
NCT00588770 2026-03-03Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNational Cancer Institute (NCI)Phase 3 Active not recruiting403 enrolled 10 charts
NCT06047379 2026-03-02Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.Phase 1/2 Recruiting134 enrolled